PDS Biotechnology Corporation - PDSB

SEC Filings Our PDSB Tweets

About Gravity Analytica

Recent News

10.20.2026 - PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
10.06.2026 - PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
09.22.2026 - PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
09.14.2026 - PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
09.08.2026 - PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
08.13.2026 - PDS Biotech Reports Second Quarter 2026 Financial Results
08.11.2026 - PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
04.15.2026 - PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
03.24.2026 - PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
01.28.2026 - PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Recent Filings